PCM
IMDX

Poehling Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Poehling Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed – – 215
2018
Q2 		$0 Buy
+3
New +$148 ﹤0.01% 320
2018
Q1 		– Sell
-3
Closed – – 328
2017
Q4 		$0 Buy
+3
New +$338 ﹤0.01% 292

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Poehling Capital Management's IMDX Position: Q3 2018 in Review

Poehling Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q3 2018, closing a stake of 3 shares.

Poehling Capital Management first reported a position in IMDX in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 26 funds tracked by Wall St. Rank hold IMDX as of Q3 2018.

  • Poehling Capital Management reported no remaining Insight Molecular Diagnostics position as of Q3 2018 after selling out during the quarter.
  • Poehling Capital Management sold 3 Insight Molecular Diagnostics shares in Q3 2018.
  • Poehling Capital Management first reported a position in Insight Molecular Diagnostics in Q4 2017 and held it in 2 quarters.
  • Poehling Capital Management's Insight Molecular Diagnostics position peaked at $0 in Q2 2018.
  • 26 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2018.

Based on Poehling Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.